Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsUpgradesPrice Target
Piper Sandler analyst Allison Bratzel upgrades enGene Therapeutics (NASDAQ:ENGN) from Neutral to Overweight and maintains the price target from $4 to $4.
Piper Sandler analyst Allison Bratzel upgrades enGene Therapeutics (NASDAQ:ENGN) from Neutral to Overweight and maintains the price target from $4 to $4.